8 articles with PainReform
PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
PainReform Ltd., a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announced the appointment of Ilan Hadar as Chief Executive Officer.
PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors
PainReform Ltd. welcomes Dr. Ellen Baron as a member of the Company's Board of Directors following its recent initial public offering.
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors
PainReform Ltd. (NASDAQ:PRFX) , welcomes Augustine Lawlor as a member of the Companys Board of Directors following its recent initial public offering.
PRF-110 addresses potential concerns in the local administration of anesthetic related to wound healing and suture integrity that are commonly involved in surgical procedures
PainReform Ltd.today announced that following the closing of its initial public offering, it has commenced preparations for the launch of its pivotal Phase 3 clinical trials of PRF-110 for the treatment of post-operative pain.
PainReform Ltd. (NASDAQ:PRFX) today announced the closing on September 3, 2020 of its initial public offering of 2,500,000 units at a price of $8.00 per unit.
PainReform Ltd has received FDA approval to conduct two pivotal Phase III clinical trials for post-operative pain relief in soft and hard tissue.
PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc.